We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Solasia

News List

Solasia enters new license alliance with Maruho biospectrumasia
December 12, 2019
Japan based Solasia Pharma K.K. has announced that it has entered into an exclusive license agreement with Maruho Co., Ltd. for the commercialization of Solasia’s product SP-04 (PledOx®), a therapeutic agent for chemotherapy induced peripheral neuropathy
Solasia initiates Phase III programme for PledOx biospectrumasia
January 07, 2019
In November 2017, Solasia acquired exclusive development and commercialization rights for PledOx in Japan, Mainland China, Hong Kong, S.A.R., China Region in China, Macau, S.A.R., China Region in China, Taiwan, China Region in China, South Korea and from
Solasia announces Episil approval in Japan biospectrumasia
July 11, 2017
Episil oral liquid is the first approved product in Japan for local treatment of pain associated with oral mucositis (OM) for cancer patients undergoing chemotherapy and radiotherapy.